





PTO/SB/08A (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/076,691		
		Filing Date	February 14, 2002		
		First Named Inventor	Shepard, Michael H		
		Art Unit	1632		
		Examiner Name	Dave Nguyen		
Sheet	1	of	2	Attorney Docket Number	016930-000630US

FEB 20 2004


U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
D	1.	6,348,352 B1	02-18-2002	Shepard et al.	2
	2.	USSN 07/948,289	N/A (Filed 09-18-1992)	Shepard et al.	
	3.	USSN 08/379,168	N/A (Filed 01-27-1995)	Shepard et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	4.	WO	94/06910	A1	03-31-1994	Canji, Inc.		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	4/28/04
-----------------------	--	--------------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60129755 v1



PTO/SB/08B (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/076,691		
		Filing Date	February 14, 2002		
		First Named Inventor	Shepard, Michael H.		
		Art Unit	1632		
		Examiner Name	Dave Nguyen		
Sheet	2	of	2	Attorney Docket Number	016930-000630US

FEB 20 2004

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DN</i>	5.	KOLATA, G., "In the rush toward gene therapy, some see a high risk of failure," <u>The New York Times</u> ; page C3, Tuesday, July 25, 1995.	
<i>J</i>	6.	LIM, B. et al., "Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells" <u>Proc Natl Acad Sci U S A</u> . 86:8892-8896 (1989).	
<i>J</i>	7.	ORKIN, S. et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy" December 7, 1995.	

Examiner Signature	<i>DN</i>	Date Considered	4/28/04
-----------------------	-----------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+

1

+

1

1.

Complete if Known

Application Number	08/403,797
Filing Date	December 4, 1995
First Named Inventor	Shepard, H. Michael
Group Art Unit	1633
Examiner Name	Dave Nguyen
Attorney Docket Number	016930-000600US

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

JC973 U.S. PTO
 10/07669
 02/14/02

JC973 U.S. PTO
 10/07669
 02/14/02

JC973 U.S. PTO
 10/07669
 02/14/02

JC973 U.S. PTO
 10/076697
 02/14/02

JC973 U.S. PTO
 10/07669
 02/14/02

JC973 U.S. PTO
 10/07669
 02/14/02

JC973 U.S. PTO
 10/07669
 02/14/02

JC973 U.S. PTO
 10/07669
 02/14/02

JC973 U.S. PTO
 10/076697
 02/14/02

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
	Application Number	08/403,797	
	Filing Date	December 4, 1995	
	First Named Inventor	Shepard, H. Michael	
	Group Art Unit	1633	
	Examiner Name	Dave Nguyen	
	Attorney Docket Number	016930-000600US	

Sheet **2** of **5**

10/07/97
10/07/97
02/14/02

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
D	11	Anderson, "Human Gene Therapy," <i>Science</i> , 256:808-813 (1992)	
	12	Baker et al., "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53," <i>Science</i> , 249:912-915 (1990)	
	13	Callahan, "p53 Mutations, Another Breast Cancer Prognostic Factor," <i>J. Natl. Canc. Inst.</i> , 84(11):826-827 (1992)	
	14	Casey et al., "Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene," <i>Oncogene</i> , 6:1791-1797 (1991)	
	15	Chen et al., "Genetic Mechanisms of Tumor Suppression by the Human p53 Gene," <i>Science</i> , 250:1576-1580 (1990)	
	16	Chen et al., "Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate," <i>Oncogene</i> , 6:1799-1805 (1991)	
	17	Cheng et al., "Suppression of acute Lymphoblastic Leukemia by the Human Wild-Type p53 Gene," <i>Cancer Research</i> , 52(1):222-226 (1992)	
	18	Correll et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 86:8912-8916 (1989)	
	19	Crystal, R.G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," <i>Science</i> , 270:404-410 (1995)	
	20	Danos et al., "Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges," <i>Proc. Natl. Acad. Sci. (U.S.A.)</i> , 85:8460-8464 (1988)	
	21	Droz et al., "Long-term Survivors after Salvage High Dose Chemotherapy with Bone Marrow Rescue in Refractory Germ Cell Cancer," <i>Eur. J. Cancer</i> , 27(7):831-835 (1991)	
	22	Finlay et al., "The p53 Proto-oncogene can act as a Suppressor of Transformation," <i>Cell</i> , 57:1083-1093 (1989)	
	23	Friedmann, T., <i>Cancer Supp</i> , 70(6):1810-1817 (1991)	
	24	Gaidano et al., "p53 mutations in human lymphoid malignancies Association with Burkitt lymphoma and chronic lymphocytic leukemia," <i>Proc. Natl. Acad. Sci. (U.S.A.)</i> , 88:5413-5417 (1991)	
	25	Gerwin et al., "Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β ," <i>Proc. Natl. Acad. Sci. (U.S.A.)</i> , 89:2759-2763 (1992)	

Examiner Signature		Date Considered	4/28/04
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1317330 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/403,797
		Filing Date	December 4, 1995
		First Named Inventor	Shepard, H. Michael
		Group Art Unit	1633
		Examiner Name	Dave Nguyen
		Attorney Docket Number	016930-000600US
Sheet	3	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Dr	26	Guild et al., "Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection," <i>Proc. Natl. Acad. Sci. (USA)</i> , 85:1595-1599 (1988)	
	27	Gutierrez et al., "Gene therapy for Cancer," <i>The Lancet</i> , 339:715-721 (1992)	
	28	Isaacs et al., "Wild-Type p53 Suppresses Growth of Human Prostate Cancer Cells Containing Mutant p53 Alleles," <i>Cancer Research</i> , 51:4718-4720 (1991)	
	29	Isola et al., "Association of Overexpression of Tumor Suppressor Protein p53 with Rapid Cell Proliferation and Poor Prognosis in Node-Negative Breast Cancer Patients," <i>J. Natl. Canc. Inst.</i> , 84(14):1109-1114 (1992)	
	30	Johnson et al., "Expression of Wild-Type p53 is not Compatible with Continued Growth of p53-Negative Tumor Cells," <i>Molecular and Cellular Biology</i> , 11(1):1-11 (1991)	
	31	Lavigne et al., "High Incidence of Lung, Bone, and Lymphoid Tumors in Transgenic Mice Overexpressing Mutant Alleles of the p53 Oncogene," <i>Molecular and Cell Biology</i> , 9(9):3982-3991 (1989)	
	32	Ledley et al., "Clinical Considerations in the Design of Protocols for Somatic Gene Therapy," <i>Human Gene Therapy</i> , 2:77-83 (1991)	
	33	Lee, "Tumor suppressor genes: a new era for molecular genetic studies of cancer," <i>Breast Cancer Research and Treatment</i> , 19:3-13 (1991)	
	34	Levine et al., "The p53 tumour suppressor gene," <i>Nature</i> , 351:453-456 (1991)	
	35	Malkin et al., "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms," <i>Science</i> , 250:1233-1238 (1990)	
	36	Miller et al., "Gene Transfer by Retrovirus Vectors Occurs Only in Cells That Are Actively Replicating at the Time of Infection," <i>Molecular and Cellular Biology</i> , 10 (8) :4239-4242(1990)	
	37	Miller et al., "p53 Mutations in Human Lung Tumors," <i>Cancer Research</i> , 52:1695-1698 (1992)	
	38	Nigro et al., "Mutations in the p53 gene occur in diverse human tumour types," <i>Nature</i> , 342:705-708 (1989)	
	39	Rill et al., "An Approach for the Analysis of Relapse and marrow Reconstitution After Autologous Marrow Transplantation Using Retrovirus-Mediated Gene Transfer," <i>Blood</i> , 79(10):2694-2700 (1992)	
	40	Rotter et al., "p53 and Human malignancies," <i>Advances in Cancer Research</i> , 57:257-272 (1991)	

Examiner Signature		Date Considered	4/28/04
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1317330 v1

Please type a plus sign (+) inside this box →



PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/403,797
		Filing Date	December 4, 1995
		First Named Inventor	Shepard, H. Michael
		Group Art Unit	1633
		Examiner Name	Dave Nguyen
		Attorney Docket Number	016930-000600US
Sheet	4	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DN</i>	41	Shaw et al., "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line," <i>Proc. Natl. Acad. Sci. (U.S.A.)</i> , 89:4495-4499 (1992)	
	42	Sikora, K., "Gene therapy for cancer," <i>TIBTECH</i> , 11:197-201 (1993)	
	43	Srivastava et al., "Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome," <i>Nature</i> , 348:747-749 (1990)	
	44	Takahashi et al., "The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells," <i>Proc Natl. Acad Sci. (U.S.A.)</i> , 88:5257-5261 (1991)	
	45	Takahashi et al., "Wild-type but not Mutant p53 Suppresses the Growth of Human Lung Cancer Cells Bearing Multiple Genetic Lesions," <i>Cancer Research</i> , 52:2340-2343 (1992)	
	46	Thor et al., "Accumulation of p53 Tumor Suppressor Gene Protein: An Independent marker of Prognosis in Breast Cancers," <i>J. Natl. Canc. Inst.</i> , 84(11):845-855 (1992)	
	47	Shaw et al., "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 89(10):4495-4499 (1992)	
	48	Yerly-Motta et al., "Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells," <i>Leuk. Lymphoma</i> , 23 (3-4) :313-321(1998)	
	49	Pei et al., "Preliminary application of a low molecular weight tumor suppressor in purged autologous bone marrow transplantation," <i>The Cancer Journal</i> , Vol. 5 (1992)	
	50	Cone et al., <i>PNAS</i> , 81:6349-6353 (1984)	
	51	Pei et al., EMBASE database, AN: 92206003, <i>Cancer Journal</i> , 5/3:142-145 (1992)	
	52	Chen et al., <i>Oncogene</i> , 6:1799-1805 (1991)	
	53	Friedmann, <i>Cancer Supplement</i> , 70,8:1810-1817 (1992)	
	54	Huang et al., <i>Science</i> , 242:1563-1568 (1988)	
	55	Masdasingelo et al., <i>Seminars In Oncology</i> , 23,1:4-21 (1996)	
Examiner Signature	<i>DN</i>		Date Considered 4/28/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1317330 v1

Please type a plus sign (+) inside this box →

+

PTO/SB/088 (08-00)

Approved for use through 10/31/2002: OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	08/403,797
		Filing Date	December 4, 1995
		First Named Inventor	Shepard, H. Michael
		Group Art Unit	1633
		Examiner Name	Dave Nguyen
		Attorney Docket Number	016930-000600US
Sheet	5	of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DM	56	Cuiver et al., "Gene therapy for solid tumors," <i>British Medical Bulletin</i> , 51:192-204 (1995)	
J	57	Carbone et al., "In vivo gene therapy of human lung cancer using wild-type p53 delivered by a retrovirus," <i>J. Natl. Cancer Inst.</i> , 86:1437-1438 (1994)	
J	58	Huang et al., "Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells," <i>Science</i> , 242:1563-1566 (1988)	

Examiner Signature	<i>DM</i>	Date Considered	4/28/04
--------------------	-----------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1317330 v1